Bicara awards CFO Jennifer Larson stock option for 285,000 shares at $24.63 each

BCAX•2026-08-14

CFO stock option grant

Bicara Therapeutics granted CFO Jennifer Larson a non-qualified stock option for 285,000 shares under its 2026 Inducement Plan.

The exercise price was set at $24.63 per share, matching the Nasdaq close on Aug. 12, 2026.

The vesting schedule provides for 25% vesting on the first anniversary of her start date, with the remainder vesting in 12 equal quarterly installments.

Bicara awards CFO Jennifer Larson stock option for 285,000 shares at $24.63 each

CFO stock option grant

Related News

Oconee Federal Financial Corp. Announces Annual Financial Results

Better Home & Finance Holding Board Reviews Communications Indicating Possible Securities Law Violations By Vishal Garg

Algorhythm net loss from continuing operations widens to $4.15 million in Q2 FY26; net sales more than doubled to $3.01 million

Valvoline Chief Accounting Officer Jordan M. Denny acquires 1,506 shares for $50,023.2

Diodes prices USD 325 million private offering of 0% convertible senior notes due 2031